Shares of Aldeyra Therapeutics (ALDX) have experienced downward price drops and high volatility primarily due to binary clinical and regulatory setbacks, including Complete Response Letters (CRLs) from the FDA regarding its lead dry eye disease candidate, reproxalap. Because clinical-stage biotech stocks depend heavily on successful regulatory approvals and commercial milestones, delays or requests for additional trials create immediate valuation corrections and investor sell-offs.